全文获取类型
收费全文 | 264篇 |
免费 | 24篇 |
国内免费 | 2篇 |
专业分类
基础医学 | 22篇 |
口腔科学 | 2篇 |
临床医学 | 32篇 |
内科学 | 94篇 |
皮肤病学 | 8篇 |
神经病学 | 15篇 |
特种医学 | 3篇 |
外科学 | 6篇 |
综合类 | 6篇 |
眼科学 | 5篇 |
药学 | 10篇 |
中国医学 | 1篇 |
肿瘤学 | 86篇 |
出版年
2023年 | 11篇 |
2022年 | 7篇 |
2021年 | 7篇 |
2020年 | 14篇 |
2019年 | 14篇 |
2018年 | 20篇 |
2017年 | 14篇 |
2016年 | 10篇 |
2015年 | 12篇 |
2014年 | 14篇 |
2013年 | 21篇 |
2012年 | 7篇 |
2011年 | 10篇 |
2010年 | 11篇 |
2009年 | 12篇 |
2008年 | 9篇 |
2007年 | 12篇 |
2006年 | 6篇 |
2005年 | 9篇 |
2004年 | 5篇 |
2003年 | 4篇 |
2002年 | 5篇 |
2001年 | 7篇 |
2000年 | 2篇 |
1999年 | 4篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1995年 | 5篇 |
1994年 | 3篇 |
1993年 | 2篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1989年 | 3篇 |
1988年 | 3篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 1篇 |
1984年 | 6篇 |
1983年 | 3篇 |
1982年 | 1篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1978年 | 1篇 |
排序方式: 共有290条查询结果,搜索用时 234 毫秒
281.
283.
284.
285.
Ibrutinib changed the landscape of treatment in Waldenström macroglobulinaemia (WM) with excellent responses; however, there are high rates of dose reduction due to adverse events. The impact of this reduced dosing is unclear with regards to outcomes. Sarosiek and colleagues provide valuable data in a very large retrospective study demonstrating that dose reduction is effective in managing adverse events in the majority, with equivalent, if not better, outcomes than those without dose reductions. 相似文献
286.
287.
289.
Chiara Briani Sergio Ferrari Tamara Berno Andrea Visentin Mario Cacciavillani Tiziana Cavallaro Marny Fedrigo Stefania Rizzo Alessandro Salvalaggio Livio Trentin Francesco Piazza 《Journal of the peripheral nervous system : JPNS》2023,28(2):262-265
Aim
Neuropathy is a frequent complication of Waldenström's macroglobulinemia (WM), the most common being a demyelinating polyneuropathy with anti-myelin associated glycoprotein (MAG) antibodies, but also cryoglobulins, vasculitis, neurolymphomatosis, and amyloidosis. We describe a patient with IgM/kappa WM who presented with a severe, not length-dependent, peripheral neuropathy as clinical onset of IgM/kappa-related amyloidosis.Methods
A 69-year-old woman came to our attention for weight loss, gait imbalance and sensory loss at upper limbs. In her medical history, she was in hematological follow-up for WM, and had undergone left carpal tunnel release. At neurological evaluation she had weakness and loss of sensation at upper limbs up to the elbows, more at the left side, gait was unsteady with right foot drop. Hypotrophy and areflexia were present at four limbs. Sensory loss and vibration sense were dramatically reduced. She underwent extensive diagnostic workup.Results
Laboratory workup revealed an IgM/kappa monoclonal paraprotein of 16 g/L and increased NT-proBNP; anti-MAG antibodies were absent. Bone marrow biopsy demonstrated a population of neoplastic B-lymphocytes. Total-body CT scan and echocardiogram were negative. Neurophysiology revealed a symmetric, no length dependent sensory-motor polyneuropathy Periumbilical fat biopsy was positive for amyloid. Sural nerve biopsy detected amyloid in the wall of an epineurial vein.Conclusions
This case report describes a rare and unusual manifestation of IgM-related AL amyloidosis in WM. The patient presented with a subacute clinically asymmetric neuropathy with no pain or dysautonomic features as clinical onset of IgM/kappa-related amyloidosis. Sural nerve biopsy was crucial for the diagnosis. 相似文献290.
《Allergology international》2023,72(3):385-393
Cryopyrin-associated periodic syndromes (CAPS) and Schnitzler syndrome (SchS) are autoinflammatory diseases that present with urticaria-like rashes. CAPS is characterized by periodic or persistent systemic inflammation caused by the dysfunction of the NLRP3 gene. With the advent of IL-1-targeted therapies, the prognosis of CAPS has improved remarkably. SchS is considered an acquired form of autoinflammatory syndrome. Patients with SchS are adults of relatively older age. The pathogenesis of SchS remains unknown and is not associated with the NLRP3 gene. Previously, the p.L265P mutation in the MYD88 gene, which is frequently detected in Waldenström macroglobulinemia (WM) with IgM gammopathy, was identified in several cases of SchS. However, because persistent fever and fatigue are symptoms of WM that require therapeutic intervention, it is a challenge to determine whether these patients truly had SchS or whether advanced WM was misidentified as SchS. There are no established treatments for SchS. The treatment algorithm proposed with the diagnostic criteria is to use colchicine as first-line treatment, and systemic administration of steroids is not recommended due to concerns about side effects. In difficult-to-treat cases, treatment targeting IL-1 is recommended. If targeted IL-1 treatment does not improve symptoms, the diagnosis should be reconsidered. We hope that the efficacy of IL-1 therapy in clinical practice will serve as a stepping stone to elucidate the pathogenesis of SchS, focusing on its similarities and differences from CAPS. 相似文献